ADx NeuroSciences

Executive Summary

ADx NeuroSciences is a privately held Belgian diagnostics company dedicated to developing novel antibodies and innovative immunoassays for quantifying biomarkers across neurodegenerative disorders, including Alzheimer's, Parkinson's, and motor neuron diseases. Founded in 2008 and headquartered in Ghent, the company focuses on enabling early and accurate diagnosis by providing high-quality research tools and potential clinical assays. Its proprietary antibody portfolio targets key pathological proteins such as tau, amyloid-beta, and alpha-synuclein. ADx collaborates with academic and industry partners to validate and commercialize its assays, positioning itself as a key enabler in the neurodegenerative diagnostics space. The company operates in a growing market, driven by an aging population and increasing demand for biomarker-based diagnostics. Despite being private, ADx has established a strong scientific reputation through publications and partnerships. However, it faces competition from established players like Quanterix and Roche. Near-term catalysts include potential partnerships with large pharma for drug trial companion diagnostics, expansion of its assay menu for emerging biomarkers, and possible funding rounds to scale commercialization. The company's success hinges on continued innovation and adoption of its assays in research and clinical settings.

Upcoming Catalysts (preview)

• Q3 2026New assay launch for blood-based tau biomarkers70% success
• 2026Pharmaceutical partnership for clinical trial biomarker testing60% success
• 2027Series B or later-stage financing round50% success